Skip to main content

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

 February 16, 2021 09:15 ET

OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

Earlier this year, the company announced that it had entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) trial. Last week, approval was received from the Dutch local Ethics Committee, clearing the road for execution of the trial.

The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects. This will assess the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. The subjects will receive intranasal dosing every other day for 13 days, for a total of seven doses each. AIM is funding the clinical study.

“We are delighted and honored to receive Ethics Committee approval, an important step toward initiation of the trial,” said AIM CEO Thomas K. Equels. “We are on track for site initiation later this month and expect to begin enrolling participants in the study during the first quarter of 2021. Importantly, our prior in vitro modeling at The Institute for Antiviral Research at Utah State University demonstrated that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage concentrations. As a result, we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of COVID-19 and are excited to commence safety tests of potential dosing regimens.”

Dr. Matthijs Moerland, principal investigator at CHDR: “We’re very happy helping AIM with this important step. Together with AIM’s study team, we feel we have not only designed a trial evaluating Ampligen’s intranasal safety profile, but also yielding important mechanistic data on the compound’s immunomodulatory activities.”

Popular Posts in the Last 7 Days

Why Brigitte Huber may be the most important AIDS and Chronic Fatigue Syndrome researcher

A Perplexity conversation about self-deceit, conspiracy, Arendt and AIDS

Perplexity names the AIDS Paradigm 20

From Perplexity A.I.: A major nosological mistake in AIDS—meaning a fundamental error in how the disease is defined, classified, or diagnosed—could be the most consequential nosological error in history because of several deeply impactful social, scientific, and ethical consequences.

HHV-8 which is found in AIDS and Chronic Fatigue Syndrome may be an Arbovirus. Are HHV-6 and HHV-7 arboviruses? Is Kaposi's Sarcoma spread by ticks?

The Harvard scholar who tried to blow the whistle

From Perplexity A.I.: List 20 questions that would make the HIV establishment (which has demonized critics of the HIV theory) uncomfortable.

Memo to CFS patients and CFS quacks: Let's get something straight.

Popular Post in the Last 30 Days

Memo to CFS patients and CFS quacks: Let's get something straight.

From Perplexity A.I.: List 20 questions that would make the HIV establishment (which has demonized critics of the HIV theory) uncomfortable.

How Kaposi's Sarcoma almost undermined the HIV theory of AIDS

Important and provocative books about HHV-6 and the epidemics it may be causing available from Amazon in print editions or on Kindle:

From Perplexity: Here are 20 ways the pharmaceutical industry should reorient their AIDS efforts based on Rebecca Culshaw’s Substack critique of the HIV paradigm:

Perplexity names the AIDS Paradigm 20

Popular Posts from the Last Year

Perplexity on Rebecca Culshaw Smith, and PrEP as Genocide

Why Brigitte Huber may be the most important AIDS and Chronic Fatigue Syndrome researcher

From Perplexity A.I.: A major nosological mistake in AIDS—meaning a fundamental error in how the disease is defined, classified, or diagnosed—could be the most consequential nosological error in history because of several deeply impactful social, scientific, and ethical consequences.

Oral Kaposi's Sarcoma looks like the Crimson Crescents in Chronic Fatigue Syndrome patients.

How Kaposi's Sarcoma almost undermined the HIV theory of AIDS

If the establishment decides that the nosology of AIDS is wrong and HIV is not the cause of AIDS could that be considered a Black Swan event?

Fauci Held in Contempt!

All Time Most Popular Posts

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

Anthony Fauci was part of the gang that silenced and destroyed Judy Mikovits.

Was Judy Mikovits destroyed because her XMRV work would have ultimately shown HIV is a total fraud?

Is Chronic Fatigue Syndrome the other AIDS epidemic in the gay community?